Monoclonal antibodies against claudin-18 for treatment of cancer

US8425902B2 · kind B2 · utility

Assignees

• Ganymed Pharmaceuticals GmbH · DE
• Johannes Gutenberg-Universität Mainz · DE

Inventors

• Ugur Sahin · Mainz, DE
• Ozlem Tureci · Homburg, DE
• Gunda Brandenburg · Mainz, DE
• Dirk Usener · Wiesbaden, DE

Key dates

• Filing date: May 27, 2008
• Grant date: Apr 23, 2013
• Expiry date: Oct 14, 2028

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/734
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, cancer of the gallbladder, and the metastases thereof.